TY - JOUR
T1 - Management of Metastatic Nonclear Renal Cell Carcinoma
T2 - What Are the Options and Challenges?
AU - EAU Section of Oncological Urology (ESOU) Board
AU - Mir, Maria Carmen
AU - Albiges, Laurence
AU - Bex, Axel
AU - Hora, Milan
AU - Giannarini, Gianluca
AU - Volpe, Alessandro
AU - Rouprêt, Morgan
N1 - Publisher Copyright:
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - This case presents a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma (RCC) with multiple bone lesions. The patient underwent a single resection of skull bone lesion (diagnostic for poorly differentiated carcinoma of unknown origin) and cytoreductive nephrectomy. The pathology of the kidney specimen demonstrated an oncocytic papillary RCC. Within 3 mo, she developed skeletal progressive disease and was started on systemic therapy (sunitinib). After initial stabilization, bone metastasis progressed during the third cycle of sunitinib and required second-line therapy (cabozantinib). One of the major unmet needs in non-clear cell RCC is the lack of specific systemic therapy. Data on immunotherapy are still limited. Inclusion of these patients in clinical trials is strongly recommended. PATIENT SUMMARY: Patients with metastatic kidney cancer who present with the less common histological subtype (non-clear cell) have poor survival. In this case, the patient responded to second-line therapy. Very few therapies provide response to treatment. Patients should be offered participation in clinical trials testing combinations with immunotherapy.
AB - This case presents a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma (RCC) with multiple bone lesions. The patient underwent a single resection of skull bone lesion (diagnostic for poorly differentiated carcinoma of unknown origin) and cytoreductive nephrectomy. The pathology of the kidney specimen demonstrated an oncocytic papillary RCC. Within 3 mo, she developed skeletal progressive disease and was started on systemic therapy (sunitinib). After initial stabilization, bone metastasis progressed during the third cycle of sunitinib and required second-line therapy (cabozantinib). One of the major unmet needs in non-clear cell RCC is the lack of specific systemic therapy. Data on immunotherapy are still limited. Inclusion of these patients in clinical trials is strongly recommended. PATIENT SUMMARY: Patients with metastatic kidney cancer who present with the less common histological subtype (non-clear cell) have poor survival. In this case, the patient responded to second-line therapy. Very few therapies provide response to treatment. Patients should be offered participation in clinical trials testing combinations with immunotherapy.
KW - Immune checkpoint blockade
KW - Kidney
KW - Metastasis
KW - Mutation
KW - Neoplasm
KW - Renal cancer
UR - http://www.scopus.com/inward/record.url?scp=85096181178&partnerID=8YFLogxK
U2 - 10.1016/j.euo.2020.05.010
DO - 10.1016/j.euo.2020.05.010
M3 - Article
C2 - 32553707
AN - SCOPUS:85096181178
SN - 2588-9311
VL - 4
SP - 843
EP - 850
JO - European urology oncology
JF - European urology oncology
IS - 5
ER -